Financial Performance - Total revenue for the six months ended September 30, 2022, was HKD 817,353,000, representing an increase of 8.92% compared to HKD 750,413,000 for the same period in 2021[8]. - Revenue from proprietary drugs increased by 3.5% to HKD 581,891,000, while revenue from brand healthcare products surged by 25.09% to HKD 235,462,000[8]. - Gross profit for the period was HKD 340,429,000, reflecting a 24.77% increase from HKD 272,842,000 in the previous year, with a gross margin of 41.7%[8]. - Profit attributable to equity holders increased by 70.16% to HKD 136,192,000, with a profit margin of 16.7%[8]. - Adjusted EBITDA rose by 42.48% to HKD 290,457,000, with an adjusted EBITDA margin of 35.5%[8][9]. - Operating profit surged by HKD 84.1 million or 71.9% to HKD 201.0 million, attributed to increased sales demand and improved product mix[72]. - Net profit rose significantly by HKD 64.5 million or 77.8% to HKD 147.4 million, reflecting the increase in operating profit despite higher financing costs and taxes[78]. - Basic and diluted earnings per share rose to HKD 7.10, up from HKD 4.18, reflecting a 69.5% increase[162]. - Total comprehensive income for the period was HKD 114,148,000, compared to HKD 75,474,000 in the previous year, marking a 51.2% increase[162]. Assets and Liabilities - Total assets as of September 30, 2022, were HKD 5,055,953,000, up 6.95% from HKD 4,755,540,000[8]. - Total liabilities increased by 14.14% to HKD 2,051,768,000, compared to HKD 1,797,575,000 in the previous period[8]. - Total equity rose by 2.59% to HKD 3,004,185,000, from HKD 2,957,965,000[8]. - Current liabilities decreased significantly to HKD 384,798,000 from HKD 826,384,000, a reduction of 53.5%[165]. - The company's equity attributable to shareholders rose to HKD 2,527,638,000 from HKD 2,491,316,000, an increase of 1.5%[165]. Market and Product Development - The company aims to expand its market presence in Asia and enhance its product offerings through strategic investments in R&D[12][16]. - The company is strategically expanding its product portfolio to strengthen its leadership position in the rapidly growing market of specialty drugs and biosimilars[18]. - The company launched several new products during the reporting period, including Trimetazidine Modified Release Tablets and Olmesartan Tablets[27]. - A total of 21 new products have received registration approval and are set to be launched soon[28]. - The company is currently developing 177 products, with 59 approved for registration and 14 submitted for registration[29]. Production and Operations - Overall production of liquid formulations increased by over 969,000 liters, a growth of 93.2% compared to the same period last year, driven by rising demand for cold and flu medications[30]. - The production of eye drop products grew strongly by 50.1% to over 27,000 liters, supported by the optimization of the sterile preparation production line and the introduction of new products from R&D projects[30]. - Total production of solid dosage forms reached over 1.754 billion capsules and tablets, an increase of 14.7% year-on-year, following the commissioning of a new oral solid production line[30]. - Semi-solid dosage production totaled approximately 175.6 tons, reflecting a year-on-year growth of 13.0%[31]. Financial Management and Investments - The company has allocated HKD 98,449,000 for expanding bioequivalence clinical research, with HKD 78,001,000 already utilized and HKD 20,448,000 remaining[88]. - The company maintains a conservative capital management approach, ensuring a solid foundation for future business development and acquisitions[89]. - The company has successfully refinanced bank loans amounting to HKD 1.4 billion during the reporting period, resulting in a significant reduction of pledged assets[91]. - The company has not conducted any significant acquisitions or disposals of subsidiaries, associates, or joint ventures during the reporting period[95]. Shareholder Information - As of September 30, 2022, the company had a total of 1,171,988,000 shares held by Mr. Chan, representing 60.59% of the issued share capital[128]. - The company has a significant shareholder structure, with Mr. Chan holding 71.10% of the shares, equating to 635,478,375 shares[129]. - Kingshill and Trust Co collectively own approximately 43.98% of the company, representing 850,684,000 shares[137]. - The company has a stock option plan that allows for the issuance of up to 138,000,000 shares, which is about 7.13% of the total issued shares as of September 30, 2022[144]. Compliance and Governance - The audit committee, consisting of three independent non-executive directors, oversees the financial reporting and risk management systems of the company[111]. - The interim financial report was reviewed and found to comply with the relevant provisions of the Hong Kong Accounting Standards[159]. - The company has implemented various measures to ensure compliance with environmental regulations, with no significant non-compliance issues reported during the period[102]. - The company believes that risk management is crucial for operational efficiency and effectiveness, with management actively assessing major risks[100].

Financial Performance - Total revenue for the fiscal year 2022 reached HKD 1,800,000, an increase from HKD 1,600,000 in 2021, representing a growth of 12.5%[5] - The profit attributable to equity holders for the fiscal year 2022 was HKD 300,000, up from HKD 250,000 in 2021, marking a 20% increase[5] - Adjusted EBITDA for the fiscal year 2022 was HKD 500,000, reflecting a decrease from HKD 441,614 in 2021, which is a decline of 5.4%[6][13] - Gross profit for the fiscal year 2022 was HKD 620,522, an increase of 10.6% compared to HKD 561,083 in 2021[13] - The gross profit margin for the fiscal year 2022 was 38.9%, slightly up from 38.8% in 2021[13] - Total revenue increased by 10.3% to HKD 1,595.5 million, demonstrating resilience despite market challenges[27] - Non-patent drug business achieved a robust growth of 13.6%, with revenue reaching HKD 1,191.3 million[27] - The profit for the year increased by HKD 82.5 million or 78.4%, excluding the one-time employment support from the Hong Kong government[76] - Adjusted net profit for the year was approximately HKD 187.7 million, up about HKD 82.5 million or 78.4% compared to the previous year[29] - Operating profit for fiscal year 2022 rose by HKD 4.7 million or 1.8% to HKD 260.9 million, driven by significant growth in the non-patent drug segment[69] Assets and Liabilities - Total assets as of March 31, 2022, were HKD 4,755,540, a decrease of 2.3% from HKD 4,867,150 in 2021[13] - Total liabilities decreased by 10.4% to HKD 1,797,575 from HKD 2,007,041 in 2021[13] - Total equity increased by 3.4% to HKD 2,957,965 from HKD 2,860,109 in 2021[13] - The net capital debt ratio decreased from 38.4% as of March 31, 2021, to 29.2% as of March 31, 2022, primarily due to the repayment of bank loans[91] Strategic Initiatives - The company aims to enhance its core capabilities and product pipeline to maintain strong performance despite ongoing challenges in the healthcare sector[14] - The company aims to expand its product offerings by introducing complex and specialty drugs, leveraging research and development investments to meet future health needs[18] - The company is focused on building strong partnerships through licensing agreements to enhance its product pipeline with complex and specialty drugs[18] - The company continues to expand its product portfolio and enhance R&D capabilities to address unmet medical needs[24] - The company actively seeks collaboration opportunities with local and overseas R&D institutions to develop innovative pharmaceutical products[24] Market Position and Growth - The company has established a leading position in various therapeutic areas, including respiratory, cardiovascular, and central nervous system[24] - The private sector showed significant recovery with a growth rate of 14.5%[27] - The trend of increasing non-patent drug usage is expected to positively impact the local market, especially with several blockbuster patents expiring soon[50] - The post-pandemic era is expected to sustain growth in the consumer healthcare market, driven by increased health awareness and online shopping trends[51] Product Development and Innovation - The company successfully launched several new specialty drugs, including Rabeprazole Tablets and Atosiban Injection, contributing to a diversified product portfolio[18] - A total of 12 products have completed the development process and have been submitted to the Hong Kong Health Department for approval[38] - The company is currently developing 172 products, with 54 approved for registration and 15 submitted for registration[38] - The company has received registration approvals for multiple upcoming products, including Levetiracetam Tablets and Febuxostat Tablet[43] - A new prescription drug for treating narcolepsy has been introduced, which is a global first and offers a better treatment experience[44] Corporate Governance - The board consists of seven members, including three executive directors, one non-executive director, and three independent non-executive directors[103] - The company has complied with all provisions of the corporate governance code during the reporting period, except for a specific provision regarding the separation of roles between the chairman and CEO[98] - The company has adopted a code of conduct for securities trading by directors, ensuring compliance throughout the reporting period[100] - The company has established risk management policies to monitor and control operational and financial performance[115] - The company aims to maintain high standards of corporate governance and recognizes the benefits of board diversity[140] Risk Management - The company has established a risk management framework that includes real-time reporting of risks exceeding the group's risk appetite[175] - The company has identified major risks including regulatory compliance in the pharmaceutical manufacturing sector, which could significantly impact operations if not adhered to[192] - The company employs a mixed approach to identify risks, utilizing both top-down and bottom-up methods[174] - Identified risks are categorized into financial, operational, reputational, legal and regulatory, and personnel risks[174] Financial Stability - The company secured a syndicated loan of HKD 1.4 billion from multiple major banks, enhancing its financial stability and supporting long-term strategic goals[18] - The financing amount has been fully utilized for refinancing bank loans and meeting general operational funding needs[95] - The company reported a robust cash flow situation, maintaining a capital debt ratio below 30%[18] Shareholder Engagement - The company is focused on maintaining effective communication with shareholders through various channels, ensuring their opinions and concerns are addressed[186] - The company allows shareholders holding at least 10% of the paid-up capital to request a special general meeting within two months of submission[180] - The company has a policy for handling and disclosing inside information, ensuring compliance with applicable laws and regulations[177]

迎接挑戰 推進轉型 雅各臣科研製藥有限公司 根據開曼群島法例註冊成立的有限公司 股份代號 : 2633 二零二一年中期報告 | --- | --- | |--------------------|----------------------------------| | | | | | | | | | | | | | 目錄 | | | | | | | | | 2 | 23 | | 公司資料 | 致董事會的審閱報告 | | | | | 3 | 24 | | 財務摘要 | 未經審核綜合損益及其他全面收益表 | | | | | 4 | 26 | | 企業願景及使命 | 未經審核綜合財務狀況表 | | | | | | | | 5 | 27 | | 公司簡介 | 未經審核綜合權益變動表 | | 6 管理層討論及分析 | 28 未經審核簡明綜合現金流量表 | | 17 其他資料 | 29 未經審核中期財務報告附註 | | | 43 | | | 詞彙 | | | | | | | | | | | | | | | | | | | | | | 公司資料 董事會 執行董事 岑廣業先生 （主席兼行政總裁） 嚴振亮先生 潘裕慧女士 獨 ...

迎接挑戰 推進轉型 雅各臣科研製藥有限公司 根據開曼群島法例註冊成立的有限公司 股份代號 : 2633 二零二一年年報 | --- | --- | --- | |-------|---------------------------|----------------------------------| | | | | | | | | | | | | | | | | | | | | | | 目錄 | | | | | | | | 1 公司資料 | 64 獨立核數師報告 | | | 2 | 69 | | | | | | | 財務摘要 4 | 綜合損益及其他全面收益表 71 | | | 主席致股東函件 6 | 綜合財務狀況表 72 | | | 企業願景及使命 7 公司簡介 | 綜合權益變動表 73 綜合現金流量表 | | | 8 管理層討論及分析 | 74 財務報表附註 | | | | | | | 20 企業管治報告 | 137 五年財務概要 | | | 32 環境、社會及管治報告 | 138 詞彙 | | | 48 董事報告書 | | 公司資料 董事會 執行董事 岑廣業先生 （主席兼行政總裁） 嚴振亮先生 潘裕慧 ...

專注於長遠發展重點 雅各臣科研製藥有限公司 根據開曼群島法例註冊成立的有限公司 股份代號: 2633 二零二零年中期報告 目錄 2 公司資料 3 財務摘要 4 企業願景及使命 5 公司簡介 6 管理層討論及分析 18 其他資料 25 致董事會的審閱報告 26 未經審核綜合損益及其他全面收益表 28 未經審核綜合財務狀況表 29 未經審核綜合權益變動表 30 未經審核簡明綜合現金流量表 31 未經審核中期財務報告附註 47 詞彙 | --- | --- | --- | --- | |-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|------------------------------------------------------------------------ ...

專注於長遠發展重點 雅各臣科研製藥有限公司 根據開曼群島法例註冊成立的有限公司 股份代號 : 2633 二零二零年年報 目錄 1 公司資料 2 財務摘要 4 致股東函件 6 企業願景及使命 7 公司簡介 8 管理層討論及分析 26 企業管治報告 38 環境、社會及管治報告 58 董事報告書 71 獨立核數師報告 76 綜合損益及其他全面收益表 78 綜合財務狀況表 79 綜合權益變動表 80 綜合現金流量表 81 財務報表附註 149 五年財務概要 150 詞彙 公司資料 董事會 執行董事 岑廣業先生 （主席兼行政總裁） 嚴振亮先生 潘裕慧女士 非執行董事 林誠光教授 獨立非執行董事 林烱堂醫生 楊俊文先生 黃志基教授 審核委員會 楊俊文先生（主席） 林烱堂醫生 黃志基教授 薪酬委員會 林烱堂醫生（主席） 楊俊文先生 潘裕慧女士 提名委員會 黃志基教授（主席） 林烱堂醫生 楊俊文先生 嚴振亮先生 授權代表 嚴振亮先生 潘裕慧女士 公司秘書 嚴振亮先生 註冊辦事處 Cricket Square Hutchins Drive PO Box 2681 Grand Cayman KY1-1111 Cayman Isl ...

加速發展策略 實現可持續成長 Accelerating Our Strategies For Sustainable Growth JACOBSON PHARMA CORPORATION LIMITED 雅各臣科研製藥有限公司 2019 INTERIM REPORT 中期報告 JACOBSON PHARMA CORPORATION LIMITED Incorporated under the laws of the Cayman Islands with limited liability Stock Code : 2633 Interim Report 2019 雅各臣科研製藥有限公司 根據開曼群島法例註冊成立的有限公司 股份代號: 2633 二零一九年中期報告 目錄 2 公司資料 3 財務摘要 5 公司簡介 27 | --- | --- | |------------------|----------------------------------| | | | | | 致董事會的審閱報告 | | | 28 | | | 未經審核綜合損益及其他全面收益表 | | | 29 | | 企業願景及使命 | 未經審 ...

加速發展策略 實現可持續成長 Illustration by Rosanna Tasker 雅各臣科研製藥有限公司 根據開曼群島法例註冊成立的有限公司 股份代號 : 2633 二零一九年年報 目錄 66 獨立核數師報告 71 綜合損益及其他全面收益表 72 綜合財務狀況表 73 綜合權益變動表 74 綜合現金流量表 75 財務報表附註 137 五年財務概要 138 詞彙 1 公司資料 2 財務摘要 4 致股東函件 6 企業願景及使命 7 公司簡介 8 管理層討論及分析 25 企業管治報告 37 環境、社會及管治報告 51 董事報告書 | --- | --- | --- | |-------|--------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------| | | | | | | 楊俊文先生（主席） 林烱堂 ...